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ABSTRACT  
Background: In the phase I KEYNOTE-001 study, pembrolizumab demonstrated durable 
antitumor activity in patients with advanced non-small cell lung cancer (NSCLC). We sought to 
characterize the relationship between pembrolizumab dose, exposure, and response to define an 
effective dose for these patients.  
 
Methods: Patients received pembrolizumab 2 mg/kg every 3 weeks (Q3W) (n = 55), 10 mg/kg 
Q3W (n = 238), or 10 mg/kg Q2W (n = 156). Response (RECIST v1.1) was assessed every 9 
weeks. The relationship between the estimated pembrolizumab area under the concentration-time 
curve at steady-state over 6 weeks (AUCss-6weeks) and the longitudinal change in tumor size (sum 
of longest diameters) was analyzed by regression and nonlinear mixed effects modeling. This 
model was simultaneously fit to all tumor size data, then used to simulate response rates, 
normalizing the trial data across dose for prognostic covariates (tumor PD-L1 expression and 
EGFR mutation status). The exposure-safety relationship was assessed by logistic regression of 
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pembrolizumab AUCss-6weeks versus occurrence of adverse events of interest based on their 
immune etiology. 
 
Results: Overall response rates were 15% (95% confidence interval [CI] 7%-28%) at 2 Q3W, 
25% (18%-33%) at 10 Q3W, and 21% (95% CI 14% to 30%) at 10 Q2W. Regression analyses of 
percentage change from baseline in tumor size versus AUCss-6week indicated a flat relationship 
(regression slope P > 0.05). Simulations showed the exposure-response relationship to be 
similarly flat, thus indicating that the lowest evaluated dose of 2 mg/kg Q3W to likely be at or 
near the efficacy plateau. Exposure-safety analysis showed the adverse event incidence to be 
similar among the clinically tested doses. 
 
Conclusions: No significant exposure dependency on efficacy or safety was identified for 
pembrolizumab across doses of 2 mg/kg to 10 mg/kg. These results support the use of a 2-mg/kg 
Q3W dosage in patients with previously treated, advanced NSCLC. 
 
ClinicalTrials.gov registry: NCT01295827 
Keywords: exposure-response; immunotherapy; non-small cell lung cancer; pembrolizumab; 
PD-L1; tumor size modeling 
Key message  
An integrated analysis of the relationship among exposure to pembrolizumab, longitudinal 
changes in tumor size, and immune-mediated adverse events observed in KEYNOTE-001 
supports pembrolizumab 2 mg/kg every 3 weeks as an appropriate dose for previously treated 
NSCLC. 
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INTRODUCTION 
Pembrolizumab is a potent, highly selective, humanized IgG4 monoclonal antibody against the 
immune checkpoint programmed death 1 (PD-1) that has a binding affinity for the PD-1 ligands 
PD-L1 and PD-L2 in the low nanomolar concentrations (PD-L1 half-maximal inhibitory 
concentration [IC50], ~0.1 to 0.3 nM and PD-L2 IC50, ~0.5 to 0.9 nM). Consistent with other 
monoclonal antibodies, pembrolizumab has a low clearance (0.2 L/day), limited central (3.7 L) 
and peripheral (4.4 L) volume of distribution, and low to moderate variability (22% to 41%) [1-
3]. The half-life is 14-22 days, and serum exposure appears linear over the range of 0.1 to 10 
mg/kg at steady-state dosing. Pembrolizumab has demonstrated robust antitumor activity and 
manageable toxicity across multiple dosages in several advanced malignancies. Pembrolizumab 
2 mg/kg every 3 weeks (Q3W) was approved through the US Food and Drug Administration 
accelerated approval program for previously treated, PD-L1–positive advanced non-small cell 
lung cancer (NSCLC). A pooled analysis of the first 495 patients with previously treated or 
treatment-naive advanced NSCLC enrolled in the multicohort phase Ib KEYNOTE-001 study 
(ClinicalTrials.gov identifier, NCT01295827) demonstrated acceptable toxicity and durable 
antitumor activity for pembrolizumab, the magnitude of which was dependent on tumor PD-L1 
expression [4].   
 
We present an integrated analysis including efficacy and safety data from the final NSCLC 
expansion cohort of KEYNOTE-001. This final cohort, which included patients with previously 
treated NSCLC who received pembrolizumab 2 mg/kg Q3W only, was excluded from the initial 
publication by Garon et al [4] because it was not part of the planned training or validation sets 
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for PD-L1 expression. We also describe a comprehensive exposure-response model based on 
tumor size data that was developed using all available NSCLC data from KEYNOTE-001 and 
employed for pembrolizumab dose selection in advanced NSCLC. This approach has become 
increasingly common for evaluating growth dynamics and treatment response in oncology [5-7] 
and is well suited for integrating and normalizing data from different time points and treatment 
durations.  
 
METHODS 
Study design 
KEYNOTE-001 is a multicenter, open-label, phase Ib trial that included multiple advanced 
NSCLC expansion cohorts. Eligibility criteria for the first 495 patients enrolled were reported 
previously [4]. Key eligibility criteria for the final cohort included age ≥18 years, locally 
advanced or metastatic NSCLC, disease progression after platinum-based chemotherapy and an 
appropriate tyrosine kinase inhibitor for a sensitizing EGFR mutation or ALK translocation if 
present, Eastern Cooperative Oncology Group (ECOG) performance status 0–1, PD-L1 
positivity, adequate organ function, no history of pneumonitis, and no systemic 
immunosuppressive therapy or active autoimmune disease.  
 
All patients provided written informed consent. The study was conducted in accordance with the 
protocol, good clinical practice standards, and the Declaration of Helsinki. All protocols and 
amendments were approved by the appropriate institutional review board or ethics committee at 
each participating institution.  
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Treatment and assessments  
In the initial KEYNOTE-001 NSCLC cohorts, 489 of 495 patients received pembrolizumab 10 
mg/kg Q3W or 10 mg/kg every 2 weeks (Q2W); the final six patients received pembrolizumab 2 
mg/kg Q3W before the protocol was amended  [4]. Based on data from a randomized 
comparison in melanoma showing no difference between pembrolizumab 2 and 10 mg/kg Q3W 
[8], a final NSCLC cohort was added in which patients received pembrolizumab 2 mg/kg Q3W. 
Patients received pembrolizumab until disease progression assessed per immune-related response 
criteria [9] by investigator review, intolerable toxicity, or investigator or patient decision. Dose 
delay, prolonged dosing interval, or discontinuation were used to manage toxicity; dose 
reduction was not allowed. Tumor lesions were measured using computed tomography or 
magnetic resonance imaging at baseline and every 9 weeks thereafter. Tumor size was recorded 
as the sum of the longest diameters (SLD) assessed per RECIST v1.1 [10] by independent central 
review. Adverse events (AEs) were collected throughout the study and for 30 days after 
treatment discontinuation (90 days for serious AEs) and graded according to National Cancer 
Institute Common Terminology Criteria for Adverse Events, version 4.0. AEs of special interest 
based on immune etiology (“immune-mediated AEs”) were identified from a prespecified list of 
terms (Table S1) and reported regardless of attribution to treatment by the investigator.  
 
PD-L1 expression was assessed in contemporaneous biopsy samples using 
immunohistochemistry and the 22C3 anti-human PD-1 antibody (Merck) [4]. For enrollment, 
expression was prospectively assessed using a prototype assay, with positivity defined as 
membranous staining on ≥1% of cells within tumor nests or staining in stroma. The PD-L1 tumor 
proportion score (TPS), defined as the percentage of tumor cells with membranous PD-L1 
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staining, was retrospectively assessed using a clinical trial assay, with positivity defined as TPS 
≥1%. Based on the findings by Garon et al [4], PD-L1 positivity was further categorized as TPS 
1% to 49% or ≥50%.  
 
Blood samples (3.5 mL) for peak and trough pharmacokinetic assessment were collected 
regularly throughout treatment (Supplementary Materials). Regardless of treatment schedule, 
samples were collected at baseline and week 6. Pembrolizumab serum concentration was 
assessed using an electrochemiluminescence-based immunoassay with a 10-ng/mL limit of 
quantitation.  
 
Exposure-Efficacy Analysis 
A tiered evaluation approach was employed as part of a comprehensive evaluation, starting with 
more traditional comparisons of observed efficacy data (exploratory regression analyses) and 
followed by nonlinear mixed effects (NLME) modeling. Data analysis conducted in a stratified 
manner for the early analyses was pooled for the NLME model of change from baseline in tumor 
size because the model’s statistical framework was better suited for integrating data.   
 
All patients who had pharmacokinetic data and measurable disease per RECIST v1.1 by central 
review at baseline were included in the exposure-efficacy regression and NLME modeling 
analyses (n = 496: n = 6 treatment-naive and 47 previously treated patients received 2 Q3W, n = 
45 treatment-naive and 216 previously treated received 10 Q3W, and n = 39 treatment-naive and 
143 previously treated received 10 Q2W). Exposure was defined as the area under the 
concentration-time curve at steady state over 6 weeks (AUCss-6weeks), derived from an 
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independent population pharmacokinetic model (manuscript submitted for publication). AUCss-
6weeks was chosen as the exposure metric because it provided an integer number of dosing 
intervals across Q2W and Q3W regimens; steady state was selected for convenience and because 
pembrolizumab exhibits linear pharmacokinetics. A common steady-state exposure metric was 
used to avoid potential confounding between early study drop-out unrelated to 
dose/pharmacokinetic variability and cumulative exposure (ie, patients who progressed early and 
discontinued treatment ultimately had lower total exposure to pembrolizumab than those treated 
for a longer duration). Such a correlation could artificially manifest as a positive exposure-
response relationship if a time-dependent exposure metric was chosen. Moreover, because 
pembrolizumab exhibits linear and time-independent pharmacokinetic behavior, AUCss-6weeks was 
expected to be a reasonable proxy exposure for all patients (eg, those who had lower AUCss-6weeks 
are expected to have proportionally lower AUC0-anytime earlier during treatment). 
 
Efficacy was defined as change from baseline in the SLD of target lesions (ie, tumor size). 
Change in tumor size was considered an appropriate efficacy measure given the demonstrated 
relationship between changes in tumor size and overall survival in NSCLC [5,11,12]. Before 
NLME modeling, an exploratory regression analysis was performed to evaluate observed change 
in SLD versus pembrolizumab exposure at a single post-baseline time point. Particular emphasis 
was placed on weeks 18 and 27 because at the time of analysis, these were the latest common 
imaging time points reached by the majority of patients remaining on study who were treated at 2 
mg/kg and 10 mg/kg. 
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Tumor size NLME model structure 
All tumor size data were used simultaneously to fit the NLME model. At 2 mg/kg, the majority 
of data were up to 18 weeks of follow-up, although six patients were observed for >1 year; 
together with the 10-mg/kg dose groups, these data were used to inform long-term model 
behavior.  
 
The tumor size model is illustrated in Figure S1 and is described mathematically as 
  
 
 
where “Baseline” is the actual measured tumor size (SLD) at initial screening, kgrowth is the first-
order tumor growth rate, kdeath is the rate constant that captures the kinetics of net removal in the 
responding portion of the tumor, and “delay” is the delay between baseline and the first dose. 
Both kgrowth and kdeath were constrained to be positive during estimation, with individual 
parameters log normally distributed.  
 
A fraction (f) of total tumor diameter was assumed to be accessible to treatment, with the 
remaining portion (1-f) undergoing exponential growth. This model parameterization is similar to 
previous models in the literature and was sufficiently flexible to capture different patterns of 
tumor growth observed for NSCLC, as well as for many other solid tumors in pembrolizumab-
treated patients.  
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To account for the effect of drug exposure, AUCss-6weeks was incorporated into the structural 
model parameterization on the tumor kill rate by assuming a log-linear relationship:  
 
 
 
Results from the independent population pharmacokinetics model provided post hoc clearance 
(CL) estimates, with plasma exposure within the dosing interval at steady state calculated as 
dose/CL. Here, TVkdeath denotes  the typical value of kdeath in the population;  “AUCtypical,ss-6weeks” 
(7079 mg/L × day) is used to normalize exposure values. The estimated value of θ determines 
the extent of the pembrolizumab exposure-response in NSCLC. Only observed tumor sizes were 
used for the modeling, with no imputations for missing data. 
 
The patient-specific factors of PD-L1 expression level, smoking history, ECOG performance 
status, demographics (age, sex, and weight), baseline tumor size, prior treatment, and EGFR 
mutation status were tested for inclusion in the model using the stepwise covariate modeling 
function of PsN [13] (forward inclusion  at P < 0.01 and backward exclusion  at P < 0.001). The 
Supplementary Methods, including Figures S1-S4 and Tables S2-S6, provide further details on 
the handling of covariates. 
 
Trial simulations  
Response rate simulations were conducted to normalize for potential data imbalances with 
respect to covariates and dose/exposure. The expected dose-response relationships based on the 
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modeled exposure-tumor size response were determined using uncertainty simulations based on 
the final model-estimated parameters. Briefly, 1000 draws were made from the parameter 
distributions, and for each set of population parameters, a trial with 1000 patients resampled with 
replacement from the observed dataset at each dose was simulated, accounting for interindividual 
and residual variability. SLD output from model simulations was categorized as response (SLD 
reduction from baseline ≥30%), stable disease (change in SLD from baseline between −30% and 
+20%), and progressive disease (≥20% increase in SLD from baseline); these categories were 
analogous to standard RECIST v1.1 categories [10] except that nontarget and new lesions were 
not considered when categorizing response. The median and 90% confidence interval (CI) of the 
proportion of patients in each category were tabulated across the 1000 uncertainty replicate 
simulations and plotted across the range of doses studied to graphically demonstrate the 
relationship between tumor size and exposure. 
 
Exposure-Safety Relationship 
Patients enrolled in all NSCLC cohorts of KEYNOTE-001 who had pharmacokinetic data were 
included in an analysis of the relationship between pembrolizumab AUCss-6weeks and the 
incidence of immune-mediated AEs. Logistic regression was used to analyze the frequency of 
immune-mediated AEs.  
 
RESULTS 
Efficacy and Safety of Pembrolizumab 2 mg/kg Q3W: Clinical Observations  
Between April 3, 2014, and July 14, 2014, 55 patients with previously treated NSCLC received 
pembrolizumab 2 mg/kg Q3W. Patient characteristics were as expected for a previously treated 
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advanced NSCLC population (Table S7). As of the January 23, 2015, data cutoff date, all 
patients had a minimum follow-up duration of 27 weeks; 15 (27%) patients remained on 
pembrolizumab. The most common reason for discontinuation was disease progression (n = 20; 
36%).  
 
The overall response (ORR) and disease control (DCR) rates per RECIST v1.1 by central review 
were 15% and 50%, respectively, in patients with measurable disease at baseline (n = 52) (Table 
1). ORR was 30% in patients with PD-L1 TPS ≥50% (n = 23), 0% in patients with TPS 1% to 
49% (n = 23), and 25% in patients with TPS <1% (n = 4). Decreases from baseline in tumor size 
were observed for 67% of patients with known PD-L1 expression treated at 2 mg/kg (Figure 1). 
Among patients treated at 10 mg/kg in randomized cohorts with similar inclusion criteria as the 
2-mg/kg cohort, including the amount of prior therapy and requirement for PD-L1 positivity per 
the prototype assay at baseline, decreases from baseline were observed in 66% of patients treated 
at Q3W and 63% treated at Q2W (Figure 1); ORR and DCR were similar to those of patients 
treated with pembrolizumab 2 mg/kg (Table 1).  
 
Treatment-related AEs were reported for 26 (47%) patients treated with pembrolizumab 2 mg/kg 
Q3W. Five (9%) patients reported grade 3–5 treatment-related AEs (n = 2 grade 3 colitis, n = 1 
grade 5 cardiorespiratory arrest, n = 1 grade 4 pneumonitis, and n = 1 grade 3 pneumonitis). The 
treatment-related death occurred in a 75-year-old man who was hospitalized on day 30 for 
possible pneumonia; 3 days later, he died from cardiopulmonary arrest considered by the 
investigator to be possibly related to pembrolizumab. Three (5%) patients discontinued treatment 
because of drug-related AEs (n = 1 each grade 5 cardiorespiratory arrest, grade 4 pneumonitis, 
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and grade 3 pneumonitis). Immune-mediated AEs occurred in 9 (15%) patients: colitis (n = 2 
grade 3, n = 1 grade 1), hypothyroidism (n = 2 grade 2, n = 1 grade 1), pneumonitis (n = 1 grade 
3, n = 1 grade 4), and exfoliative dermatitis (n = 1 grade 1). Considering all 550 patients with 
NSCLC enrolled in KEYNOTE-001, the AE profile observed at 2 mg/kg Q3W was mostly 
similar to that observed in patients treated at higher dosages (Table 2).  
 
Exploratory Regression and Model-Based Analyses of the Exposure-Efficacy Relationship 
Observed tumor size data showed a wide range of longitudinal response patterns across the 
previously treated population. At week 18, 170 previously treated patients had both tumor size 
and exposure data. Exploratory graphical analysis of observed tumor size and exposure data from 
these patients showed a flat relationship between exposure and change from baseline in tumor 
size at 18 weeks, with overlapping CIs observed between subsets defined by binned AUCss-6weeks 
(Figure 2). The linear regression slope estimates were not significantly different from zero, with 
P values greater than the prespecified significance level (>0.05), regardless of whether the data 
were pooled or stratified by PD-L1 expression (Figure S5).  
 
In agreement with the exploratory graphical and linear regression analyses of the data observed 
at week 18, individual pembrolizumab exposures (across all patients) also showed no statistically 
significant influence on the model-estimated tumor shrinkage rate in an NLME analysis of the 
exposure-response relationship (P = 0.54 based on −2 log-likelihood reduction and χ2 test). The 
95% CIs of the exposure response parameter were found to overlap with zero (point estimate, 
0.196; range, −0.0784 to 0.47), consistent with no significant difference from a flat exposure-
response relationship. PD-L1 expression (Figure 3 and Table S5) and EGFR mutation (Table 
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S5) status were the only factors found that explained a significant portion of interindividual 
variability in longitudinal tumor size patterns, with the impact of these factors found to be 
independent of dose. (Full details of structural model selection and analysis of covariate effects 
are found in the Supplementary Materials.) 
 
Exposure-Response Simulations  
Model-simulated median response rates at week 27 for patients with PD-L1 TPS ≥50% were 
39% (90% CI 31% to 46%) at 2 mg/kg Q3W, 40% (90% CI 34% to 45%) at 10 mg/kg Q3W and 
44% (90% CI 37% to 49%) at 10 mg/kg Q2W (Figure 3A). The CIs for patients with PD-L1 
TPS 1% to 49% also showed overlap (Figure 3B), and the relationship between kdeath and 
exposure for PD-L1 TPS <1% was similarly flat (data not shown). 
 
 Exposure-Safety Relationship 
A total of 544 patients were evaluable for the relationship between exposure and safety. Logistic 
regression analysis identified treatment duration as a significant factor for occurrence of 
immune-mediated AEs. After inclusion of treatment duration in the model, no significant 
relationship between pembrolizumab exposure assessed as AUCss-6weeks and immune-mediated 
AEs was found (P = 0.57) (Figure S6). Similarly, pembrolizumab exposure was not significantly 
correlated with the hazard for the occurrence of immune-mediated AEs in the time-to-event 
analysis (P = 1.0). Apart from treatment duration, no other investigated covariate was a 
significant predictor of the probability of experiencing an immune-mediated AE. Based on 
simulations from the final logistic regression model, even when forcing a relationship with 
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pembrolizumab exposure, the predicted immune-mediated AE incidence at 9 months was similar 
for 2 mg/kg Q3W (26%), 10 mg/kg Q3W (27%), and 10 mg/kg Q2W (28%). 
 
DISCUSSION 
Based on the observed clinical data and comprehensive clinical pharmacology modeling and 
simulation, the approved 2-mg/kg Q3W dose of pembrolizumab provides clinically significant 
antitumor activity in NSCLC, with an efficacy and safety profile comparable to those observed 
with doses of 10 mg/kg Q3W or 10 mg/kg Q2W. Given that no dose-exposure-response 
dependency for efficacy or safety was identified between the 2-mg/kg and 10-mg/kg doses, the 
benefit-risk profile at the higher dose levels is not expected to be better than at 2 mg/kg Q3W.  
 
The analysis supporting these conclusions represents the first comprehensive population 
pharmacokinetic/pharmacodynamics study of a therapy targeting PD-1/PD-L1 signaling. In this 
analysis, a NLME modeling framework was used to describe the relationship between systemic 
pembrolizumab exposure and antitumor efficacy in patients with NSCLC. The implemented 
model described the treatment effect on tumor size and captured kinetics of the underlying 
intratumoral heterogeneity of response, including the tumor shrinkage rate, underlying tumor 
growth for unresponsive tumor cells, and the extent to which tumors respond in an individual 
patient. Inclusion of f allowed for an empirical description of profiles in patients whose tumor 
size increases or stabilizes to a smaller size after an initial decrease and is coherent with the 
general understanding of intratumoral response heterogeneity. One could speculate that the 
remaining 1-f tumor fraction may represent tumor cells with lower PD-L1 expression or poorly 
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perfused areas of tumor inaccessible to pembrolizumab, but these hypotheses have yet to be 
explored.  
 
To build the final model, a covariate search was conducted to identify factors important to 
NSCLC tumor growth/shrinkage patterns under pembrolizumab treatment that could be 
accounted for as part of the final exposure-response evaluation. In this way, the potential for 
imbalances and gaps in the available data to influence the exposure-response assessment was 
lessened, enhancing the robustness of the results. A relatively stringent significance level was 
used in covariate testing (P < 0.01 in the forward step, P < 0.001 in the backward step) to 
mitigate the likelihood of false positives given that multiple hypothesis testing was applied 
during the search. Using these criteria, EGFR mutation and PD-L1 expression status were 
selected as predictors of the fraction of tumor affected by treatment and the tumor kill rate, 
respectively. The impact of PD-L1 and EGFR as predictors of tumor size kinetics is not 
surprising given their established role in NSCLC cancer cell growth and the known mechanism 
of pembrolizumab. Aside from target lesion SLD, other factors can influence RECIST-based 
response assessments, including shrinkage in nontarget tumors (eg, pathologic lymph nodes) and 
appearance of malignant lesions indicative of disease progression. Because the model only 
accounted for target lesion SLD, such nuances of RECIST were not accounted for in the 
simulations. Therefore, caution is urged in interpreting the results and making direct comparisons 
with RECIST v1.1 response categories.  
 
The efficacy profile of the 2-mg/kg Q3W dose is further supported by early translational and 
biomarker pharmacokinetic/pharmacodynamic results, whereby potential clinical efficacy was 
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predicted by integrating available preclinical pharmacokinetics, PD-1 receptor occupancy and 
antitumor data from a syngeneic mouse model, early clinical pharmacokinetic data, and human 
disease properties [14]. Data from the KEYNOTE-010 study of pembrolizumab 2 and 10 mg/kg 
Q3W versus docetaxel for previously treated NSCLC support the similar efficacy and safety of 
pembrolizumab 2 and 10 mg/kg Q3W [15]. 
 
The demonstrated lack of a dose-exposure-response relationship for pembrolizumab raises the 
question of how to best determine the appropriate dose for immunotherapy. Recently, there has 
been considerable interest in optimizing dose selection for immunotherapies and other anticancer 
therapies [16,17]. Currently, most oncology dose-finding studies are designed to determine the 
maximum tolerated dose (MTD) based on the rate of prespecified dose-limiting toxicities that 
occur within a prespecified period of time, usually the first treatment cycle. However, this 
method may be outmoded for targeted therapies and immunotherapies, for which the biologically 
effective dose (BED) may be much lower than the MTD [16]. Using the MTD rather than the 
BED could expose patients to a higher dose than that necessary to achieve clinical effect and 
may increase toxicity, which could lower overall clinical effectiveness. Therefore, dose 
determination in oncology should use a multifactorial approach that includes not only clinical 
data from the first treatment cycle but extended clinical data, preclinical models, 
pharmacokinetics, pharmacodynamics, and integrated modeling and simulation [16,17]. Ideally, 
this multifactorial process would lead to a randomized dose-ranging study appropriately powered 
to identify the BED. 
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In summary, the approach reported here provides an integrated framework for exposure-efficacy 
analysis that accounts for imbalances in data and effects of explanatory covariates more 
thoroughly than those that rely exclusively on categorical end points (eg, RECIST). The final 
model adequately captured the array of diverse tumor size profiles observed in the 
pembrolizumab-treated NSCLC population and provided strong evidence for a lack of exposure 
dependency on response for the clinical dose range of 2 mg/kg Q3W to 10 mg/kg Q3W/Q2W. 
Normalization of trial data through simulations also revealed considerable overlap of response at 
these dosages. Because the model-estimated exposure-slope point estimate was slightly positive, 
the median simulated response and upper uncertainty bounds supported the possibility that there 
is a modest trend of increasing response rate and decreasing stable disease rate as dose or 
frequency is increased. However, the significant overlap in confidence intervals of the simulated 
response categories across a wide spectrum of exposures suggests antitumor response is likely 
saturated in this dose range. Therefore, it is likely that between-patient differences in 
pembrolizumab pharmacokinetics do not result in clinically relevant differences in efficacy over 
the dose range of 2 mg/kg Q3W to 10 mg/kg Q2W. Overall, the clinical data and model-based 
statistical testing and trial simulations of the magnitude of the exposure-response relationship 
support 2 mg/kg Q3W as an appropriate dose for pembrolizumab in patients with NSCLC. 
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Figure Legends 
Figure 1. Best percentage change from baseline in sum of the longest diameters of target lesions 
by PD-L1 tumor proportion score (TPS). A. Patients treated with pembrolizumab 2 mg/kg every 
3 weeks. B. Patients treated with pembrolizumab 10 mg/kg every 3 weeks. C. Patients treated 
with pembrolizumab 10 mg/kg every 2 weeks. Change from baseline in tumor size was assessed 
in patients with measurable disease at baseline by RECIST v1.1 per central review and ≥1 
evaluable postbaseline tumor assessment who had known PD-L1 TPS. 
Figure 2. Observed percentage change from baseline in tumor size at 18 weeks by 
pembrolizumab exposure. The analysis population was patients with previously treated NSCLC 
who had both tumor size and exposure data at week 18 (n = 170). AUCss-6wk is presented in 
µg∙day/mL. The sample size per group is shown. Lines extending vertically from the boxes 
(whiskers) indicate variability outside the 25th and 75th quantile. The ends of the whiskers 
correspond to the 5th and 95th quantiles of the observed data. All patients treated at 2 mg/kg are 
in the left-most bin. AUCss-6weeks, area under the concentration-time curve at steady state over a 
6-week interval; CI, confidence interval. 
Figure 3. Median simulated response rates by pembrolizumab dose spanning the observed range 
of NSCLC exposure (1000 simulated trials, each with 1000 patients). A. Patients with PD-L1 
expression in ≥50% of tumor cells at week 27. B. PD-L1 expression in 1% to 49% of tumor cells 
at week 27. PD-L1 expression was assessed using a clinical trial immunohistochemistry assay. 
Error bars represent the 90% confidence intervals around the estimates. Response was defined as 
a ≥30% decrease from baseline in SLD, stable disease was defined as a <30% decrease but <20% 
increase from baseline in SLD, and progression was defined as a ≥20% increase from baseline in 
SLD). CI, confidence interval; SLD, sum of the longest diameters. 
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Table 1. Overall response and disease control rates per RECIST v1.1 by central review in 
patients in patients with measurable disease at baseline by central review 
 Pembrolizumab 
2 mg/kg Q3W 
Pembrolizumab  
10 mg/kg Q3Wa 
Pembrolizumab 
10 mg/kg Q2Wa 
ORR, % (95% CI) 
Totalb N = 52 
15 (7–28) 
N = 155 
25 (18-33) 
N = 105 
21 (14–30) 
PD-L1 TPS ≥50%  n = 23 
30 (13–53) 
n = 42 
48 (32-64) 
n = 31 
39 (22-58) 
PD-L1 TPS 1% to 49% n = 23 
0 (0–15) 
n = 49 
14 (6-27) 
n = 43 
14 (5-28) 
PD-L1 TPS <1% n = 4 
25 (<1–81) 
n = 18 
6 (<1-27) 
n = 9 
11 (<1-48) 
DCR, % (95% CI) 
Totalb N = 52 
50 (36–64) 
N = 155 
48 (40-56) 
N = 105 
50 (40–60) 
PD-L1 TPS ≥50%  n = 23 
57 (35–77) 
n  = 42 
60 (43-74) 
n = 31 
55 (36-73) 
PD-L1 TPS 1% to 49% n = 23 
48 (27–69) 
n = 49 
39 (25-54) 
n = 43 
49 (33-65) 
PD-L1 TPS <1% n = 4 
25 (<1–81) 
n = 18 
33 (13-59) 
n = 9 
44 (14-79) 
CI, confidence interval; DCR, disease control rate; ORR, overall response rate; PD-L1, 
programmed death receptor 1 ligand 1; RECIST v1.1, Response Evaluation Criteria in Solid 
Tumors version 1.1; TPS, tumor proportion score (i.e. percentage of tumor cells with 
membranous PD-L1 expression as assessed by a clinical-trial assay). 
aIncludes only patients treated at 10 mg/kg in randomized cohorts with similar inclusion criteria 
as the 2-mg/kg cohort, including the amount of prior therapy and requirement for PD-L1 
positivity per the prototype assay at baseline. 
bIncludes patients for whom a PD-L1 TPS could not be assigned (n = 2 for 2 mg/kg and n = 90 
for 10 mg/kg). 
 
 
Table 2. Adverse event summary and duration of follow-up by dose and schedule in all patients 
with NSCLC treated in KEYNOTE-001 (N = 550) 
AE, n (%) 2 mg/kg Q3W 
(n = 61) 
10 mg/kg Q3W 
(n = 287) 
10 mg/kg Q2W 
(n = 202) 
Treatment related 
Any grade  31 (51) 201 (70) 148 (73) 
Grade 3–5 5 (8) 34 (12) 19 (9) 
Leading to 
discontinuation 
4 (7) 11 (4) 8 (4) 
Leading to death 1 (2) 1 (<1) 0 (0) 
Of special interest based 
on immune etiology 
9 (15) 39 (14) 32 (16) 
Duration of follow-up, 
mo, median (range) 
8 (6–23) 16 (10–32) 16 (10–20) 
AE, adverse event; Q2W, every 2 weeks; Q3W, every 3 weeks. 
